Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Earnings for Adagene Inc. (ADAG)
Earnings in 2023 (TTM): $-17,254,962
According to Adagene Inc.'s latest financial reports the company's current earnings (TTM) are $-17,254,962. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Adagene Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-17,254,962 | $-18,946,370 |
| 2022 | $-79,512,792 | $-79,971,847 |
| 2021 | $-71,476,322 | $-73,177,935 |
| 2020 | $-16,432,308 | $-16,435,472 |
| 2019 | $-16,432,308 | $-17,293,880 |
| 2018 | $-15,266,184 | $-14,719,181 |